In a small randomized ICU trial, a single temazepam dose did not establish an improvement in nocturnal sleep duration or reported sleep quality.
What the randomized comparison found
The blinded placebo-controlled pilot trial treated 56 ICU patients: 28 received temazepam and 28 placebo. Mean total sleep time was 349 minutes with temazepam and 291 minutes with placebo. The estimated difference was 57 minutes, with a 95% confidence interval from −11 to 130 minutes and a p value of 0.10.
Nurse and patient assessments using the Richards-Campbell Sleep Questionnaire also did not show statistically significant differences. The numerical duration difference should therefore be presented together with its uncertainty and the negative quality findings.
What remains unresolved
The confidence interval includes both no improvement and a potentially meaningful increase in duration. That does not prove equivalence, but it also does not justify claiming demonstrated efficacy. Recruitment was limited, including disruptions associated with the pandemic and staffing constraints. A single-dose pilot cannot answer questions about repeated treatment or long-term outcomes.
The outcome was sleep in a particular ICU context, not general insomnia treatment, ventilator tolerance, or freedom from all sedative adverse effects. In a clinical record, medication-induced quietness should not automatically be equated with restorative sleep. The trial’s contribution is a direct, limited test of that assumption.
Source paper
Original analysis of the supplied journal article, identified as PMC12933563.
Leave a Reply